AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of...

Related Keywords

Japan ,Spain ,Liechtenstein ,Barcelona ,Comunidad Autonoma De Cataluna ,Norway ,Iceland ,Institut Catal ,Genmab Duobody ,Roopal Thakkar ,Anna Sureda ,Us Inc ,Macrophage Propertiesj Immunol ,Exchange Commission ,Facebook ,Youtube ,Development Of Novel Anti ,Drug Administration ,European Commission ,Twitter ,European Union ,Administration Of Tepkinly ,European Medicines Agency ,Instagram ,Linkedin ,Important Safety Information ,Lysis Syndrome ,Product Characteristics ,Release Syndrome ,Full Prescribing Information ,Medication Guide ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Largeb Cell Lymphoma ,Conditional Marketing ,Accessed August ,Clinically Utilized ,Directed Antibodies ,Macrophage Properties ,Novel Anti Cd ,Cell Surface ,Cancer Sci ,Markets ,